Phenytoin Dosing in Renal Impairment
No dose adjustment of phenytoin is required based solely on renal function, but therapeutic drug monitoring must be based on unbound (free) phenytoin concentrations rather than total serum levels because protein binding is significantly reduced in renal impairment. 1, 2
Key Principle: Altered Protein Binding, Not Clearance
Phenytoin is primarily metabolized by the liver (not renally eliminated), so renal dysfunction does not directly affect drug clearance 1, 2. However, renal impairment causes a critical change in pharmacokinetics:
- Protein binding decreases from ~90% in normal patients to significantly lower levels in renal failure 2, 3
- The fraction of unbound (pharmacologically active) phenytoin increases substantially 1, 3
- This means a lower total serum concentration produces the same therapeutic effect 3
Dosing Algorithm for Renal Impairment
Standard Dosing Maintained
- Continue the same phenytoin dose as you would in patients with normal renal function 1
- Loading dose: 15-20 mg/kg IV (adults) at ≤50 mg/min 1
- Maintenance: Standard doses every 6-8 hours 1
Critical Monitoring Adjustment
Monitor unbound (free) phenytoin levels, NOT total levels 1, 3:
- Target unbound phenytoin: 1-2 mcg/mL 1
- In renal failure, a total phenytoin level of 5-10 mcg/mL may be therapeutic (versus the usual 10-20 mcg/mL target) 3
- The apparent affinity constant decreases most significantly when creatinine clearance falls below 25 mL/min 3
Specific Populations Requiring Unbound Monitoring
The FDA label explicitly states monitoring should be based on unbound fraction in 1:
- Renal disease
- Hepatic disease
- Hypoalbuminemia
- Pregnancy (due to altered protein binding)
Common Pitfall to Avoid
The most dangerous error is dose-reducing phenytoin based on "low" total serum levels in renal patients 3. This can lead to toxicity because:
- A total level of 8 mcg/mL in a dialysis patient may represent an unbound level of 2-3 mcg/mL (toxic range)
- Increasing the dose based on the "low" total level will cause seizures, ataxia, and nystagmus 2
Drug Interactions Magnified by Renal Disease
Phenytoin is a strong CYP3A4 inducer, and renal impairment can alter the metabolism of co-administered CYP3A4 substrates 4:
- Drugs like daclatasvir, sofosbuvir, and rivaroxaban have reduced efficacy when combined with phenytoin 5, 6, 7, 8
- This interaction is contraindicated for daclatasvir and "not recommended" for sofosbuvir 6, 7
Practical Implementation
Calculate an adjusted therapeutic range for total phenytoin based on albumin and creatinine clearance 3:
- Obtain baseline serum albumin and creatinine clearance
- Request unbound phenytoin levels from the laboratory (not routinely measured)
- If only total levels available, interpret cautiously: expect therapeutic effect at 50-75% of the usual total concentration range when CrCl <25 mL/min 3